Dr. Paras Batuk Ramolia, MD

Dr. Ramolia practices at Fort Wayne Dermatology Consultants Inc in Fort Wayne, Indiana.

Dr. Ramolia's NPI, 1457524167, was assigned on April 2, 2008. Dr. Ramolia graduated from Indiana University School Of Medicine in 2008. Dr. Ramolia's Texas license number on file is P1685.

Dr. Ramolia's primary practice is Fort Wayne Dermatology Consultants Inc, at 7881 Carnegie Blvd, Fort Wayne, IN 46804 in Allen County. The practice phone is (260) 436-8000.

Dr. Ramolia's primary practice is Fort Wayne Dermatology Consultants Inc in Fort Wayne, Indiana. The medical group on file is Fort Wayne Dermatology Consultants. Dmand AI also links Dr. Ramolia to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ramolia practices. Vendor and product names are available with a free account.

Dermatology is Dr. Ramolia's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Ramolia is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Ramolia's licenses on file in 2 states: Texas and Indiana.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, cold sores or genital herpes, contact dermatitis, corns and calluses and hives among the conditions Dr. Ramolia treats.

CMS data shows 7,120 Medicare services from Dr. Ramolia across 44 procedure codes in 2024, for 1,291 Medicare patients. Medicare paid $526,734 for them. Every service was in an office.

CMS counts 1,291 Medicare patients who saw Dr. Ramolia in 2024. The largest group is 65 to 74, with 598 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 3% are also on Medicaid. Their average risk score is 1.06, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ramolia's median patient age at 74, with 45% women.

In 2024, Dr. Ramolia wrote 996 Medicare Part D claims for 543 patients. 97% of them were for generic drugs. CMS names the drug for 874 of them, across 19 drugs with 11 or more claims each, at $28,551 in total drug cost. In 2023, CMS named 1,216 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Dr. Ramolia for performance year 2024, reported individually. Dr. Ramolia accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 960 procedures of removal of skin lesions by Dr. Ramolia, more than 93% of the clinicians it reports for that procedure.

Dmand AI links 5 papers to Dr. Ramolia in 2011. The most frequent topics are Skin Neoplasms. Dr. Ramolia has published most often in J Am Acad Dermatol. Dr. Ramolia's most frequent co-authors are Melissa Pam Sirichotiratana, MD, Cloyce L. Stetson, MD and Michael J. Wells, MD.

CMS Open Payments shows 804 general payments to Dr. Ramolia from 34 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 99% of the total. Abbvie Inc. paid the most, $4,006.

Dmand AI lists 1 award for Dr. Ramolia, most recently CMS Stage 1 EHR in 2013.

Dr. Ramolia graduated from Indiana University School Of Medicine in 2008.

Dr. Ramolia is in network with 20 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.